Form 4: CFO Kathleen Borthwick Granted 10,000 Passage Bio RSUs

Passage Bio's CFO, Kathleen Borthwick, was granted 10,000 restricted stock units, vesting over two years.

Summary

• Kathleen Borthwick, the Chief Financial Officer (CFO) of Passage BIO, Inc. (PASG), was granted 10,000 Restricted Stock Units (RSUs).
• The transaction date for this grant was January 15, 2025.
• These RSUs convert into common stock on a one-for-one basis.
• 50% of the total RSUs will vest on January 8, 2026, and the remaining 50% will vest on January 8, 2027.
• Vesting is contingent upon Ms. Borthwick's continued provision of service to Passage BIO on each vesting date.
• The filing also notes that a reverse stock split was effected by the issuer on July 14, 2025.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive signal for retention and alignment of interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of 10,000 Restricted Stock Units to the CFO serves to align her interests with those of the shareholders.
• Equity compensation is a standard and effective incentive for retaining key management personnel.

Risks

• The vesting of the Restricted Stock Units is subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends through January 2027, contingent on the CFO's continued service to the company, indicating a long-term incentive and retention strategy.

Industry Context

The grant of Restricted Stock Units to a key executive like the CFO is a standard practice in the biotechnology and pharmaceutical industry, often used to align management incentives with long-term shareholder value and to retain talent in a competitive market. This type of equity compensation is common across publicly traded companies, especially those in growth-oriented sectors.

Comparison to Industry Standards

• Equity compensation, specifically RSU grants, is a widely adopted practice across the biotech and broader public company landscape.
• Companies like Biogen (BIIB), Moderna (MRNA), and Gilead Sciences (GILD) frequently utilize similar long-term incentive plans for their executives to foster retention and performance alignment.
• The vesting schedule over two years is also a common structure, balancing immediate incentive with long-term commitment, comparable to practices seen in many peer companies.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term company performance. Minor dilution from future share issuance upon vesting is a consideration.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Next Steps

• Continued service by the CFO to meet RSU vesting conditions.
• Future filings will report the vesting and conversion of these RSUs into common stock.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice aimed at retention and aligning management's interests with shareholders. It does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Passage BIO, PASG, Restricted Stock Units, RSU, Equity Compensation, CFO, Kathleen Borthwick, Insider Transaction, Form 4